Department of Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
Department of Thoracic Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands.
Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):566-575. doi: 10.1093/icvts/ivab291.
Chemoradiotherapy (CRT) has been the backbone of guideline-recommended treatment for Stage IIIA non-small cell lung cancer (NSCLC). However, in selected operable patients with a resectable tumour, good results have been achieved with trimodality treatment (TT). The objective of this bi-institutional analysis of outcomes in patients treated for Stage IIIA NSCLC was to identify particular factors supporting the role of surgery after CRT.
In a 2-centre retrospective cohort study, patients with Stage III NSCLC (seventh edition TNM) were identified and those patients with Stage IIIA who were treated with CRT or TT between January 2007 and December 2013 were selected. Patient characteristics as well as tumour parameters were evaluated in relation to outcome and whether or not these variables were predictive for the influence of treatment (TT or CRT) on outcome [overall survival (OS) or progression-free survival (PFS)]. Estimation of treatment effect on PFS and OS was performed using propensity-weighted cox regression analysis based on inverse probability weighting.
From a database of 725 Stage III NSCLC patients, 257 Stage IIIA NSCLC patients, treated with curative intent, were analysed; 186 (72%) with cIIIA-N2 and 71 (28%) with cT3N1/cT4N0 disease. One hundred and ninety-six (76.3%) patients were treated by CRT alone (high-dose radiation with daily low-dose cisplatin) and 61 (23.7%) by TT. The unweighted data showed that TT resulted in better PFS and OS. After weighting for factors predictive of treatment assignment, patients with a large gross tumour volume (>120 cc) had better PFS when treated with TT, and patients with an adenocarcinoma treated with TT had better OS, regardless of tumour volume.
Patients with Stage IIIA NSCLC and large tumour volume, as well as patients with adenocarcinoma, who were selected for TT, had favourable outcome compared to patients receiving CRT. This information can be used to assist multidisciplinary team decision-making and for stratifying patients in studies comparing TT and definitive CRT.
放化疗(CRT)一直是 IIIA 期非小细胞肺癌(NSCLC)指南推荐治疗的基础。然而,在一些可手术的局部晚期患者中,采用三联治疗(TT)可获得较好的效果。本研究旨在分析接受 IIIA 期 NSCLC 治疗患者的结局,以确定支持 CRT 后手术作用的特定因素。
在一项回顾性的、两中心队列研究中,确定了第七版 TNM 分期的 III 期 NSCLC 患者,并选择了 2007 年 1 月至 2013 年 12 月期间接受 CRT 或 TT 治疗的 IIIA 期患者。评估患者特征和肿瘤参数与结局的关系,以及这些变量是否对治疗(TT 或 CRT)对结局(总生存期(OS)或无进展生存期(PFS))的影响具有预测作用。使用基于逆概率加权的倾向性评分加权 Cox 回归分析,估计治疗对 PFS 和 OS 的影响。
从 725 例 III 期 NSCLC 患者的数据库中,分析了 257 例接受根治性治疗的 IIIA 期 NSCLC 患者;其中 186 例(72%)为 cIIIA-N2,71 例(28%)为 cT3N1/cT4N0 疾病。196 例(76.3%)患者接受单纯 CRT(大剂量放疗联合每日低剂量顺铂)治疗,61 例(23.7%)患者接受 TT 治疗。未加权数据显示 TT 可改善 PFS 和 OS。对治疗分配的预测因素进行加权后,对于肿瘤体积较大(>120 cc)的患者,TT 治疗可获得更好的 PFS,而腺癌患者无论肿瘤体积大小,TT 治疗可获得更好的 OS。
对于肿瘤体积较大的 IIIA 期 NSCLC 患者,以及腺癌患者,选择 TT 治疗可获得更好的结局。这些信息可用于辅助多学科团队决策,并对 TT 和确定性 CRT 比较研究中的患者进行分层。